Visit TheBody.com for Patient Education
You are not currently logged in.
Login
or
Register
Sign up for free e-mail/fax newsletters!
New CME/CE:
An Update on New HIV Antiretroviral Agents by Edwin DeJesus, M.D. >>
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy
Antiretroviral Therapy
Acute Infection
Antiretrovirals
Assays (Diagnostic & Monitoring)
Guidelines
Initial Therapy
Pediatrics
Resistance
Salvage Therapy
Second/Third-Line Treatment
Structured Treatment Interruptions
Women & Pregnancy
More ...
Complications of HIV/HAART
Complications of HIV/HAART
Overview
Cardiovascular
Lipoatrophy
Gastrointestinal
Hepatitis
HPV & Cervical/Anal Cancer
Liver Complications
Malignancies
Mental Health
Metabolic
Neurocognitive
Renal Complications
Women-Specific
More ...
Research & Development
Research & Development
Overview
Antiretrovirals in Development
Conference Reports
HIV Genetics
HIV Immunology
More ...
Clinical Trials
Clinical Trials
Overview & News
U.S. Databases
U.S. Nationwide Studies
U.S. State-by-State Trial Listings
Databases Outside U.S.
Specific Trials Outside U.S.
More ...
Quality of Life & Patient Care
Quality of Life & Patient Care
Complementary Medicine
Mental Health
Primary Care
Nucleoside Reverse Transcriptase Inhibitor Research
General Research
|
Abacavir (Ziagen)
|
AZT (Retrovir)
|
3TC (Epivir)
|
d4T (Zerit)
|
ddI (Videx)
General Research
Nucleoside Reverse-Transcriptase Inhibitor Dosing Errors in an Outpatient HIV Clinic in the Electronic Medical Record Era
(September 1, 2007)
A study finds that HIV-infected patients with renal impairment are often prescribed incorrect NRTI doses.
In
Journal of Infectious Diseases
Patients With Renal Impairment Often Receive Wrong NRTI Dose; Particular Risk With Combination Pills
(August 16, 2007)
From aidsmap.com
Quadruple-NRTI Regimen No More Desirable Than Triple-NRTI Regimen in Treatment-Naive Patients, Study Finds
(December 16, 2005)
In
The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Two NRTIs or Three? Makes No Difference When Taken With Efavirenz, ACTG 5095 Finds
(December 16, 2005)
In
The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy